'Promising but not perfect': generics industry's take on EMA's literature monitoring service
This article was originally published in SRA
Generics companies have several reservations about the European Medicines Agency's new literature monitoring service, under which the agency intends to check several reference databases and journals for suspected adverse reactions involving 400 active substances1-3.
You may also be interested in...
As part of efforts to “renovate” its good clinical practice (GCP) framework, the International Council for Harmonisation has framed new overarching GCP principles that can be applied to diverse trial types and data sources.
The 2021 work plan of PIC/S, the international group of pharmaceutical inspectorates, includes renewed efforts to carry out projects that could not be completed due to the coronavirus pandemic.
After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a recently formed regulatory oversight group has identified several topics requiring further scientific discussion.